TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37796776

Group type: EXPERIMENTAL
Intervention: OAB participants (OAB-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (CON-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OAB participants (OAB-1)
Number of subjects: 0
Study: 37796784

Group type: EXPERIMENTAL
Intervention: LDART (Let's Do Addiction Recovery Together!) intervention used every night for a month
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LDART (Let's Do Addiction Recovery Together!) intervention
Number of subjects: 30
Study: 37796870

Group type: EXPERIMENTAL
Intervention: Myofascial induction
Number of subjects: 84

Group type: COMPARATOR
Intervention: Simulation of myofascial induction
Number of subjects: 84
Study: 37797219

Group type: EXPERIMENTAL
Intervention: Olive Oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast Milk
Number of subjects: 0
Study: 37797293

Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 360 mg
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 180 mg
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo [withdrawal]
Number of subjects: 462
Study: 37797310

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 144
Study: 37797387

Group type: EXPERIMENTAL
Intervention: Capecitabine (Cap) 2000 mg/m² day 1-14 q3w for 6 cycles plus ibandronate (Ib) 50 mg p.o. daily or 6 mg intravenous q4w for 2 years
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Ibandronate (Ib) alone for 2 years
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Cap+Ib
Number of subjects: 1358
Study: 37797404

Group type: EXPERIMENTAL
Intervention: Plasma citrulline concentration among septic patients
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Plasma LPS concentration and activity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Detection of LPS
Number of subjects: 109
Study: 37797547

Group type: EXPERIMENTAL
Intervention: Prophylactic distal perfusion cannulation (PDPC)
Number of subjects: 479

Group type: COMPARATOR
Intervention: No prophylactic distal perfusion cannulation (no-PDPC)
Number of subjects: 479
Study: 37797632

Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg and 10 mg/kg every 2 weeks (dose escalation phase)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg and a fixed dose of 450 mg every 2 weeks (dose expansion phase)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cadonilimab at 6 mg/kg every 2 weeks (phase 2)
Number of subjects: 240
Study: 37797633

Group type: EXPERIMENTAL
Intervention: Carriers of cancer predisposing variants (641 participants, 5.1%)
Number of subjects: 12469

Group type: EXPERIMENTAL
Intervention: Carriers of cancer predisposing variants
Number of subjects: 12469

Group type: COMPARATOR
Intervention: Non-carriers of cancer predisposing variants
Number of subjects: 12469
Study: 37797733

Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa (BA) with concurrent chemoradiotherapy (cCRT) followed by BA
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo with concurrent chemoradiotherapy (cCRT) followed by durvalumab
Number of subjects: 153
Study: 37797734

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 37797893

Group type: EXPERIMENTAL
Intervention: Leniolisib
Number of subjects: 37
Study: 37797965

Group type: EXPERIMENTAL
Intervention: Research participation (exposed group)
Number of subjects: 1495
Study: 37798029

Group type: EXPERIMENTAL
Intervention: Goal achievement theory-based physical activity promotion programme (16-week, face-to-face and e-health blended)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 37798422

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment for carriers of novel HNF1A variants
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Functional investigations of HNF1A variants
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Genetic sequencing for HNF1A variants
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Classification of HNF1A variants
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Prevalence estimation of HNF1A-MODY
Number of subjects: 615
Study: 37798468

Group type: EXPERIMENTAL
Intervention: Reparixin 1200 mg three times daily for up to 21 days
Number of subjects: 279
Study: 37798538

Group type: EXPERIMENTAL
Intervention: M8891 (a selective and reversible inhibitor of methionine aminopeptidase 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M8891
Number of subjects: 0
Study: 37798628

Group type: EXPERIMENTAL
Intervention: Custodiol cardioplegia (CC)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Blood cardioplegia (BC)
Number of subjects: 226
Study: 37798642

Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback system
Number of subjects: 30

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 30
Study: 37798650

Group type: EXPERIMENTAL
Intervention: HB-adMSC therapy (5 intravenous infusions of 2 × 10^6 cells)
Number of subjects: 10
Study: 37798658

Group type: EXPERIMENTAL
Intervention: Healthy Lifetime (HL) health coaching program delivered electronically over eight weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Healthy Lifetime (HL) health coaching program for individuals with high blood pressure
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study: 37798671

Group type: EXPERIMENTAL
Intervention: Florbetapir PET imaging
Number of subjects: 237

Group type: COMPARATOR
Intervention: Cognitive impairment
Number of subjects: 237
Study: 37798696

Group type: EXPERIMENTAL
Intervention: Personalized infant feeding support sessions delivered by a local professional lactation specialist, five sessions from pregnancy until three months postpartum.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personalized infant feeding support sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In-person sessions in a clinic setting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personalized professional infant feeding support sessions
Number of subjects: 20
Study: 37798723

Group type: EXPERIMENTAL
Intervention: NTHi vaccine candidate genes (pd, pe, pilA) and Mcat gene (uspA2)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: NTHi vaccine candidate genes (pd, pilA)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Mcat gene (uspA2)
Number of subjects: 123
Study: 37798756

Group type: EXPERIMENTAL
Intervention: Fascia therapy along with conventional physical therapy (hot pack, strengthening, stretching)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fascial manipulation treatment with conventional physical therapy
Number of subjects: 52
Study: 37798801

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Number of subjects: 60
Study: 37798808

Group type: EXPERIMENTAL
Intervention: CFT + AAR (after-action review)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFT as usual (standard implementation)
Number of subjects: 0
Study: 37798860

Group type: EXPERIMENTAL
Intervention: Explorer Baby early intervention program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Active control neurodevelopmental therapy (NDT)
Number of subjects: 51
Study: 37798863

Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness in T2D individuals
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness decline rate
Number of subjects: 122

Group type: COMPARATOR
Intervention: GCL + IPL thickness in ETDRS grade 20
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: GCL + IPL thickness in ETDRS grades 35 and 43-47
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Association between GCL + IPL thinning and retinal capillary non-perfusion
Number of subjects: 122
Study: 37799162

Group type: EXPERIMENTAL
Intervention: Infection prevention and control (IPC) intervention developed based on Phase 1 results and systematic literature review.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gap analysis conducted in Phase 1 to explore IPC practices among healthcare workers.
Number of subjects: 0
Study: 37799526

Group type: EXPERIMENTAL
Intervention: Intermittent teaching unit based on the use of activity wristbands and behavior modification strategies
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 175
Study: 37799613

Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg for 6 additional cycles during Extension Period)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (during First Period)
Number of subjects: 95
Study: 37799724

Group type: EXPERIMENTAL
Intervention: Omicron-adapted vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 0
Study: 37799965

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 37800112

Group type: EXPERIMENTAL
Intervention: Combination therapy with moderate-intensity rosuvastatin (RE 10) and ezetimibe (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-intensity rosuvastatin (R20)
Number of subjects: 0
Study: 37800194

Group type: EXPERIMENTAL
Intervention: Circadian Reinforcement Therapy (CRT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 103
Study: 37800325

Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography myocardial blood flow (MBF) measurement using technetium-99m-tetrofosmin
Number of subjects: 175
Study: 37800343

Group type: EXPERIMENTAL
Intervention: Hot water pack application (80°C, applied at 3, 6, 9, and 12 hours postoperatively for 30 minutes each time)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Hot water pack application
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (standardized enhanced recovery protocols)
Number of subjects: 121
Study: 37800367

Group type: EXPERIMENTAL
Intervention: Bundled interventions (nutrition and parenting)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Interventions that engaged fathers
Number of subjects: 960

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 960
Study: 37800372

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1538
Study: 37800374

Group type: EXPERIMENTAL
Intervention: Direct transport to a comprehensive stroke center (CSC) prioritizing endovascular therapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Admission to the nearest primary stroke center (PSC) prioritizing intravenous thrombolysis (IVT)
Number of subjects: 171
Study: 37800415

Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent Influenza Vaccine (HD-TIV)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine (SD-QIV)
Number of subjects: 170
Study: 37800475

Group type: EXPERIMENTAL
Intervention: Moisturizer use
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Hispanic or Latino ethnicity
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Parental education level lower than a 4-year college degree
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Living in North Carolina or Wisconsin (compared to Oregon)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Increasing child age (in days)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Pet ownership
Number of subjects: 909
Study: 37800546

Group type: EXPERIMENTAL
Intervention: Electronic patient reported outcomes (ePROs)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Paper patient reported outcomes (pPROs)
Number of subjects: 218
Study: 37800559

Group type: EXPERIMENTAL
Intervention: BR (Betamethasone-Ropivacaine) group
Number of subjects: 116

Group type: COMPARATOR
Intervention: R (Ropivacaine) group
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: BR group
Number of subjects: 116

Group type: COMPARATOR
Intervention: R group
Number of subjects: 116
Study: 37800563

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 171

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 171
Study: 37800589

Group type: EXPERIMENTAL
Intervention: Individualized risk-based surveillance for pStage II GC patients
Number of subjects: 1661

Group type: EXPERIMENTAL
Intervention: NCCN surveillance guideline for pStage III GC patients
Number of subjects: 1661

Group type: COMPARATOR
Intervention: pStage III GC patients
Number of subjects: 1661
Study: 37800597

Group type: EXPERIMENTAL
Intervention: Nivasorexant 100 mg administered twice daily (b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocktail of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4)
Number of subjects: 0
Study: 37800633

Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist/long-acting β-agonist
Number of subjects: 0
Study: 37800762

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia prevalence in low- and middle-income countries
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Functional dyspepsia prevalence in high-income countries
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prevalence of FD among Afro-Caribbean race
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Sudan
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Egypt
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Algeria
Number of subjects: 1000
Study: 37800766

Group type: EXPERIMENTAL
Intervention: Targeted therapy with osimertinib
Number of subjects: 29
Study: 37800887

Group type: EXPERIMENTAL
Intervention: Smartphone-based Hearing Aid App (Petralex; IT4YOU Corp LLC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional Hearing Aid (Siya 1 miniRITE; Oticon A/S)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unaided conditions
Number of subjects: 38
Study: 37801046

Group type: EXPERIMENTAL
Intervention: Zanamivir inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 37801052

Group type: EXPERIMENTAL
Intervention: Patient-reported symptom monitoring with real-time feedback to physicians
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patient-reported symptom monitoring
Number of subjects: 94
Study: 37801232

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 952
Study: 37801266

Group type: EXPERIMENTAL
Intervention: Zibotentan 5 mg (single oral dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (healthy matched participants)
Number of subjects: 23
Study: 37801315

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT) plus docetaxel
Number of subjects: 350
Study: 37801356

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 144000

Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 144000
Study: 37801358

Group type: EXPERIMENTAL
Intervention: SmartJournal intervention (digital tool with documentation, assessment, and education components)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SmartJournal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (existing oral care routines)
Number of subjects: 0
Study: 37801454

Group type: EXPERIMENTAL
Intervention: Dietary modification as part of lipid-lowering therapy
Number of subjects: 0
Study: 37801553

Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 300
Study: 37801622

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT-III) levels at admission and at 24 hours
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: d-dimer levels at admission and at 24 hours
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels at 24 hours
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Creatinine levels
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Progression to necrosis, infected necrosis, organ failure, and mortality
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Low AT-III and high d-dimer plasma levels at 24 hours
Number of subjects: 346
Study: 37801628

Group type: EXPERIMENTAL
Intervention: Adalimumab standard-dose induction treatment
Number of subjects: 201
Study: 37801658

Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed-Loop System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections
Number of subjects: 0
Study: 37801674

Group type: EXPERIMENTAL
Intervention: HER3-DXd 1.6-8.0 mg/kg intravenously once every 3 weeks
Number of subjects: 182
Study: 37801678

Group type: EXPERIMENTAL
Intervention: G1 AEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G2 AEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic G2 AEs
Number of subjects: 0
Study: 37801707

Group type: EXPERIMENTAL
Intervention: Double therapy (rituximab + chlorambucil)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: TTCR24
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: CR24
Number of subjects: 401
Study: 37801789

Group type: EXPERIMENTAL
Intervention: High-dose oral iron supplementation (FeSO4)
Number of subjects: 0
Study: 37801936

Group type: EXPERIMENTAL
Intervention: Usual care plus a nurse-led decision counselling programme
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study: 37801967

Group type: EXPERIMENTAL
Intervention: 60 Gy radiotherapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: 70 Gy radiotherapy
Number of subjects: 215
Study: 37802038

Group type: EXPERIMENTAL
Intervention: Single-dose intrahippocampal delivery of cryopreserved, post-mitotic, medial ganglionic eminence (MGE) pallial-type GABAergic interneurons.
Number of subjects: 0
Study: 37802088

Group type: EXPERIMENTAL
Intervention: Efruxifermin 28 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 37802221

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and elastography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liver biopsy
Number of subjects: 0
Study: 37802222

Group type: EXPERIMENTAL
Intervention: Hub-and-Spoke intervention including invitation primer, mailed fecal immunochemical test, phone and text reminders, and patient navigation protocol.
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Usual care (non-intervention clinics).
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Hub-and-Spoke intervention including patient navigation protocol.
Number of subjects: 5000
Study: 37802392

Group type: EXPERIMENTAL
Intervention: PHMB 0.02% + propamidine 0.1%
Number of subjects: 135

Group type: COMPARATOR
Intervention: PHMB 0.08% + placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 135
Study: 37802566

Group type: EXPERIMENTAL
Intervention: PGT121 + VRC07-523LS (treatment one; n=6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PGDM1400 + VRC07-523LS (treatment two; n=6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 10-1074 + VRC07-523LS (treatment three; n=6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 + VRC07-523LS (treatment four; n=9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 27
Study: 37802567

Group type: EXPERIMENTAL
Intervention: Implementation phase intervention (stepwise algorithm for HIV-related CNS infections, including bedside rapid diagnostic testing and WHO cryptococcal meningitis guidelines)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Observation phase (standard care)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Implementation phase intervention
Number of subjects: 501

Group type: COMPARATOR
Intervention: Observation phase
Number of subjects: 501
Study: 37802608

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) combined with chemotherapy and PD-1 inhibitor (toripalimab)
Number of subjects: 34
Study: 37802611

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 0
Study: 37802612

Group type: EXPERIMENTAL
Intervention: UroLift
Number of subjects: 45

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 45
Study: 37802619

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapies (OATs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Primary care recruitment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AF forum recruitment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Secondary care recruitment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: COVID-19 impact
Number of subjects: 32
Study: 37802620

Group type: EXPERIMENTAL
Intervention: Physiotherapy sessions (9 sessions) with pain ratings 4-7 out of 10 for 9 weeks and 0-2 for 3 weeks, including 15 min of manual therapy; non-supervised exercises 2×/week with physiotherapy and 3×/week without physiotherapy.
Number of subjects: 12
Study: 37802624

Group type: EXPERIMENTAL
Intervention: Technology-based intervention (iVY) including video-counselling and a mobile health app
Number of subjects: 200
Study: 37802679

Group type: EXPERIMENTAL
Intervention: Chlormethine (CL) gel
Number of subjects: 123
Study: 37803017

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 60
Study: 37803037

Group type: EXPERIMENTAL
Intervention: Spinal cord injury patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 37803096

Group type: EXPERIMENTAL
Intervention: Mirror therapy prior to robot-assisted therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham mirror therapy prior to robot-assisted therapy
Number of subjects: 37
Study: 37803098

Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop (uncontrolled diabetes subgroup)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop (controlled diabetes subgroup)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual Care (UC) at-risk participants
Number of subjects: 134